Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines

[1]  F. Tarazona-Santabalbina,et al.  Enfermedad por coronavirus 2019 (COVID-19) y edadismo: revisión narrativa de la literatura , 2020, Revista Española de Geriatría y Gerontología.

[2]  N. Bansback,et al.  Triple Therapy Versus Biologic Therapy for Active Rheumatoid Arthritis: A Cost-Effectiveness Analysis. , 2017, Annals of internal medicine.

[3]  Nil,et al.  Obesity : Physical activity and Diet , 2017 .

[4]  S. Walsh,et al.  The gathering storm: hydroxychloroquine retinopathy screening in the U.K. , 2017, The British journal of dermatology.

[5]  M. Gonzalez-Suarez,et al.  Lower kidney allograft survival in African–Americans compared to Hispanic–Americans with lupus , 2017, Lupus.

[6]  M. Marmor.  Hydroxychloroquine Screening Alert: Change is in the Wind. , 2017, Ophthalmic surgery, lasers & imaging retina.

[7]  S. Kang,et al.  Frequency and Clinical Characteristics of Hydroxychloroquine Retinopathy in Korean Patients with Rheumatologic Diseases , 2017, Journal of Korean medical science.

[8]  M. Marmor,et al.  The Prevalence of Hydroxychloroquine Retinopathy and Toxic Dosing, and the Role of the Ophthalmologist in Reducing Both. , 2016, American journal of ophthalmology.

[9]  Judy E. Kim,et al.  Update on Screening Recommendations for Hydroxychloroquine Retinopathy. , 2016, JAMA ophthalmology.

[10]  C. Gordon,et al.  Hydroxychloroquine-related retinal toxicity. , 2016, Rheumatology.

[11]  M. Marmor,et al.  Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). , 2016, Ophthalmology.

[12]  L. Magder,et al.  Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence , 2015, The Journal of Rheumatology.

[13]  M. Marmor,et al.  A Critical Review of the Effects of Hydroxychloroquine and Chloroquine on the Eye , 2015, Clinical Reviews in Allergy & Immunology.

[14]  M. Marmor,et al.  The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. , 2014, JAMA ophthalmology.

[15]  D. Browning,et al.  The impact of different algorithms for ideal body weight on screening for hydroxychloroquine retinopathy in women , 2014, Clinical ophthalmology.

[16]  R. Lew,et al.  Therapies for active rheumatoid arthritis after methotrexate failure. , 2013, The New England journal of medicine.

[17]  N. H. Rod,et al.  Additive Interaction in Survival Analysis: Use of the Additive Hazards Model , 2012, Epidemiology.

[18]  E. Borba,et al.  Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect , 2012, Lupus.

[19]  M. Walvick,et al.  Hydroxychloroquine: lean body weight dosing. , 2011, Ophthalmology.

[20]  A. Bourke,et al.  Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. , 2011, Informatics in primary care.

[21]  Michael S. Lee.  Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy , 2011 .

[22]  M. Petri.  Use of Hydroxychloroquine to Prevent Thrombosis in Systemic Lupus Erythematosus and in Antiphospholipid Antibody–Positive Patients , 2011, Current rheumatology reports.

[23]  M. Marmor,et al.  Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. , 2002, Ophthalmology.

[24]  Ş. Kobak,et al.  Retinopathy due to antimalarial drugs in patients with connective tissue diseases: are they so innocent? A single center retrospective study , 2010, International journal of rheumatic diseases.

[25]  M. Marmor,et al.  Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus , 2010, Arthritis care & research.

[26]  M. Khamashta,et al.  Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review , 2008, Annals of the rheumatic diseases.

[27]  M. Khamashta,et al.  Hydroxychloroquine: the cornerstone of lupus therapy , 2008, Lupus.

[28]  J. Ioannidis,et al.  EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics , 2007, Annals of the rheumatic diseases.

[29]  J. Reveille,et al.  Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L) , 2007, Annals of the rheumatic diseases.

[30]  L. Magder,et al.  Hydroxychloroquine in lupus pregnancy. , 2006, Arthritis and rheumatism.

[31]  Petros P Sfikakis,et al.  The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal. , 2003, Ophthalmology.

[32]  R. Carr,et al.  Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. , 2002, Ophthalmology.

[33]  W. Mieler,et al.  Information Statement Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy , 2002 .

[34]  Gerald. D. Levy,et al.  Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice. , 1997, Arthritis and rheumatism.

[35]  A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. , 1991, The New England journal of medicine.

[36]  A. Mackenzie,et al.  Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials. , 1983, The American journal of medicine.

[37]  M. McCarron,et al.  Clinical Pharmacy: Case Studies , 1974 .